Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas
Abstract Head and neck squamous cell carcinomas (HNSCC) induced by human papillomavirus (HPV) have increased recently in the US. However, the distinct alterations of molecules involved in the death pathways and drug effects targeting inhibitor of apoptosis proteins (IAPs) have not been extensively c...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d665633856e14a8a985871ecd86fdb93 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d665633856e14a8a985871ecd86fdb93 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d665633856e14a8a985871ecd86fdb932021-12-02T11:39:38ZDeath agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas10.1038/s41598-021-85589-52045-2322https://doaj.org/article/d665633856e14a8a985871ecd86fdb932021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85589-5https://doaj.org/toc/2045-2322Abstract Head and neck squamous cell carcinomas (HNSCC) induced by human papillomavirus (HPV) have increased recently in the US. However, the distinct alterations of molecules involved in the death pathways and drug effects targeting inhibitor of apoptosis proteins (IAPs) have not been extensively characterized in HPV(+) HNSCC cells. In this study, we observed the distinct genomic and expression alterations of nine genes involved in cell death in 55% HNSCC tissues, which were associated with HPV status, tumor staging, and anatomic locations. Expression of four genes was statistically correlated with copy number variation. A panel of HPV(+) HNSCC lines showed abundant TRAILR2 and IAP1 protein expression, but were not sensitive to IAP inhibitor birinapant alone, while combinatory treatment with TNFα or especially TRAIL enhanced this drug sensitivity. The death agonistic TRAILR2 antibody alone showed no cell inhibitory effects, whereas its combination with birinapant and/or TRAIL protein demonstrated additive or synergistic effects. We observed predominantly late apoptosis mode of cell death after combinatorial treatments, and pan-caspase (ZVAD) and caspase-8 (ZIETD) inhibitors attenuated treatment-induced cell death. Our genomic and expression data-driven study provides a framework for identifying relevant combinatorial therapies targeting death pathways in HPV(+) HNSCC and other squamous cancer types.Yi AnJun JeonLillian SunAdeeb DerakhshanJianhong ChenSophie CarlsonHui ChengChristopher SilvinXinping YangCarter Van WaesZhong ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-16 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Yi An Jun Jeon Lillian Sun Adeeb Derakhshan Jianhong Chen Sophie Carlson Hui Cheng Christopher Silvin Xinping Yang Carter Van Waes Zhong Chen Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas |
| description |
Abstract Head and neck squamous cell carcinomas (HNSCC) induced by human papillomavirus (HPV) have increased recently in the US. However, the distinct alterations of molecules involved in the death pathways and drug effects targeting inhibitor of apoptosis proteins (IAPs) have not been extensively characterized in HPV(+) HNSCC cells. In this study, we observed the distinct genomic and expression alterations of nine genes involved in cell death in 55% HNSCC tissues, which were associated with HPV status, tumor staging, and anatomic locations. Expression of four genes was statistically correlated with copy number variation. A panel of HPV(+) HNSCC lines showed abundant TRAILR2 and IAP1 protein expression, but were not sensitive to IAP inhibitor birinapant alone, while combinatory treatment with TNFα or especially TRAIL enhanced this drug sensitivity. The death agonistic TRAILR2 antibody alone showed no cell inhibitory effects, whereas its combination with birinapant and/or TRAIL protein demonstrated additive or synergistic effects. We observed predominantly late apoptosis mode of cell death after combinatorial treatments, and pan-caspase (ZVAD) and caspase-8 (ZIETD) inhibitors attenuated treatment-induced cell death. Our genomic and expression data-driven study provides a framework for identifying relevant combinatorial therapies targeting death pathways in HPV(+) HNSCC and other squamous cancer types. |
| format |
article |
| author |
Yi An Jun Jeon Lillian Sun Adeeb Derakhshan Jianhong Chen Sophie Carlson Hui Cheng Christopher Silvin Xinping Yang Carter Van Waes Zhong Chen |
| author_facet |
Yi An Jun Jeon Lillian Sun Adeeb Derakhshan Jianhong Chen Sophie Carlson Hui Cheng Christopher Silvin Xinping Yang Carter Van Waes Zhong Chen |
| author_sort |
Yi An |
| title |
Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas |
| title_short |
Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas |
| title_full |
Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas |
| title_fullStr |
Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas |
| title_full_unstemmed |
Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas |
| title_sort |
death agonist antibody against trailr2/dr5/tnfrsf10b enhances birinapant anti-tumor activity in hpv-positive head and neck squamous cell carcinomas |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/d665633856e14a8a985871ecd86fdb93 |
| work_keys_str_mv |
AT yian deathagonistantibodyagainsttrailr2dr5tnfrsf10benhancesbirinapantantitumoractivityinhpvpositiveheadandnecksquamouscellcarcinomas AT junjeon deathagonistantibodyagainsttrailr2dr5tnfrsf10benhancesbirinapantantitumoractivityinhpvpositiveheadandnecksquamouscellcarcinomas AT lilliansun deathagonistantibodyagainsttrailr2dr5tnfrsf10benhancesbirinapantantitumoractivityinhpvpositiveheadandnecksquamouscellcarcinomas AT adeebderakhshan deathagonistantibodyagainsttrailr2dr5tnfrsf10benhancesbirinapantantitumoractivityinhpvpositiveheadandnecksquamouscellcarcinomas AT jianhongchen deathagonistantibodyagainsttrailr2dr5tnfrsf10benhancesbirinapantantitumoractivityinhpvpositiveheadandnecksquamouscellcarcinomas AT sophiecarlson deathagonistantibodyagainsttrailr2dr5tnfrsf10benhancesbirinapantantitumoractivityinhpvpositiveheadandnecksquamouscellcarcinomas AT huicheng deathagonistantibodyagainsttrailr2dr5tnfrsf10benhancesbirinapantantitumoractivityinhpvpositiveheadandnecksquamouscellcarcinomas AT christophersilvin deathagonistantibodyagainsttrailr2dr5tnfrsf10benhancesbirinapantantitumoractivityinhpvpositiveheadandnecksquamouscellcarcinomas AT xinpingyang deathagonistantibodyagainsttrailr2dr5tnfrsf10benhancesbirinapantantitumoractivityinhpvpositiveheadandnecksquamouscellcarcinomas AT cartervanwaes deathagonistantibodyagainsttrailr2dr5tnfrsf10benhancesbirinapantantitumoractivityinhpvpositiveheadandnecksquamouscellcarcinomas AT zhongchen deathagonistantibodyagainsttrailr2dr5tnfrsf10benhancesbirinapantantitumoractivityinhpvpositiveheadandnecksquamouscellcarcinomas |
| _version_ |
1718395731185762304 |